Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01968187 · ClinicalTrials.gov registry record · Phase 2
Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT01968187 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 38 participants.
The verdict
NCT01968187, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of intranasal FE 992097 in children and adults with Prader-Willi Syndrome.
Interventions
- DRUG Placebo
- DRUG FE 992097
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-01-20 |
| Est. Completion | 2014-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01968187
The ClinicalTrials.gov registry entry for NCT01968187 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01968187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01968187 about?
NCT01968187 is a clinical study titled "Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome". The purpose of this study is to evaluate the safety and effectiveness of intranasal FE 992097 in children and adults with Prader-Willi Syndrome.
What is the current status of trial NCT01968187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2014-01-20. Estimated completion is 2014-07-16.
What interventions are being tested in trial NCT01968187?
The interventions under investigation include: Placebo (DRUG), FE 992097 (DRUG).
Who is sponsoring clinical trial NCT01968187?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.